High expression of this signature was associated with good clinical outcome in multiple ER+ breast cancer cohorts, suggesting that tumor-suppressive effects of TGF-β are still active and slowing disease progression at the time of surgery in a significant fraction of breast cancer patients. This evidence concerns the gene TGFB1 and breast carcinoma.